

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 19, 2025

HPAC

RRID:CVCL_3517

Type: Cell Line

Proper Citation

(RRID:CVCL_3517)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3517

Proper Citation: (RRID:CVCL_3517)

Sex: Female

Defining Citation: [PMID:15367885](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25939163](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Proteome analysis by 2D-DE/MS., Omics: Metabolome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Characteristics: Established from a nude mouse xenograft (ATCC=CRL-2119)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: HPAC

Synonyms: Hpac

Cross References: BTO:BTO_0004121, CLO:CLO_0003814, EFO:EFO_0002197, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2119, BCRC:60495, BioSample:SAMN03472247, BioSample:SAMN10987698, cancercellines:CVCL_3517, CCRID:1101HUM-PUMC000189,

Cell_Model_Passport:SIDM00670, ChEMBL-Cells:ChEMBL3308388, ChEMBL-Targets:ChEMBL612595, Cosmic:913306, Cosmic:1571784, Cosmic:1995444, Cosmic:2434094, Cosmic-CLP:1298136, DepMap:ACH-000270, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298136, GEO:GSM621897, GEO:GSM206509, GEO:GSM784701, GEO:GSM887089, GEO:GSM888160, GEO:GSM1024401, GEO:GSM1374545, GEO:GSM1669892, IARC_TP53:21070, IGRhCellID:HPAC, LiGeA:CCLE_795, LINCS_LDP:LCL-1735, PharmacnoDB:HPAC_564_2019, PRIDE:PXD003198, PRIDE:PXD032263, PRIDE:PXD030304, Progenetix:CVCL_3517, PubChem_Cell_line:CVCL_3517, Wikidata:Q54890226

ID: CVCL_3517

Record Creation Time: 20250131T200611+0000

Record Last Update: 20250131T201918+0000

Ratings and Alerts

No rating or validation information has been found for HPAC.

No alerts have been found for HPAC.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Schäfer TE, et al. (2024) Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. EBioMedicine, 105, 105219.

Tao J, et al. (2024) CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Journal of experimental & clinical cancer research : CR, 43(1), 277.

Hagel KR, et al. (2023) Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer research, 83(4), 613.

Paul MC, et al. (2023) Non-canonical functions of SNAIL drive context-specific cancer progression. Nature communications, 14(1), 1201.

Liu X, et al. (2023) Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. *Cancer cell*, 41(6), 1073.

Hsieh YY, et al. (2023) Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance. *Molecular oncology*.

Vallés-Martí A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. *Cell reports*, 42(6), 112581.

Wei D, et al. (2023) Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. *Digestive diseases and sciences*.

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. *Cell reports*, 42(12), 113503.

Lier S, et al. (2022) A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. *Bioorganic chemistry*, 119, 105505.

Whorowski A, et al. (2022) Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased α_2 adrenergic agonist. *Scientific reports*, 12(1), 3618.

Heid I, et al. (2022) Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. *Cancer & metabolism*, 10(1), 24.

Stalneck CA, et al. (2022) Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. *Cancer research*, 82(4), 586.

Fonteneau G, et al. (2022) Stress Granules Determine the Development of Obesity-Associated Pancreatic Cancer. *Cancer discovery*, 12(8), 1984.

Campbell S, et al. (2021) Glutamine deprivation triggers NAGK-dependent hexosamine salvage. *eLife*, 10.

He QR, et al. (2021) The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. *British journal of pharmacology*, 178(12), 2496.

Schwappacher R, et al. (2021) Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. *Cancers*, 13(15).

Klomp JE, et al. (2021) CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. *Cell reports*, 37(9), 110060.

Waters AM, et al. (2021) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. *Cell reports*, 35(13), 109291.

Kaur G, et al. (2021) Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine. *SLAS discovery : advancing life sciences R & D*, 26(10),

